trastuzumab emtansine

Ligand id: 6928

Name: trastuzumab emtansine

Compound class Antibody
Approved drug? Yes (EMA and FDA (2013))
International Nonproprietary Names
INN number INN
9295 trastuzumab emtansine
ado-trastuzumab emtansine | Kadcyla® | PRO-132365 | RG-3502
Database Links
Specialist databases
IMGT/mAb-DB 357
Other databases
GtoPdb PubChem SID 178103510
PubChem SID 178103510
Search PubMed clinical trials trastuzumab emtansine
Search PubMed titles trastuzumab emtansine
Search PubMed titles/abstracts trastuzumab emtansine
Wikipedia Trastuzumab_emtansine
Trastuzumab emtansine is a antobody-drug conjugate (ADC) containing a targeting antibody (anti-erbB2) conjugated to a cytotoxic drug (mertansine or DM1) [3]. The PubChem ID for the mertasine component compound is CID 11343137. Mertansine (or DM1) is a macrolide of the ansamycin type and can be isolated from plants of the genus Maytenus. It is known as a maytansinoid. This agent binds to the rhizoxin binding site on β- tubulin and functions in a similar fashion to the Vinca alkaloids.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Other trastazumab antibody-drug conjugates (ADCs) in development:
trastuzumab duocarmazine (SYD985; Synthon Biopharmaceuticals) [1] delivers a toxic DNA methylating compound to target cancer cells. It is in Phase 3 development.
trastuzumab deruxtecan (DS-8201; Daiichi Sankyo) delivers a topoisomerase I inhibitor payload. It is in Phase 2 clinical development.